Arrhythmia Storm in Cardiac Amyloidosis Secondary to Neglected Psoriatic Arthritis: A Case Report

Document Type : Case Report


1 Department of Cardiology and Vascular Medicine, Faculty of Medicine, Airlangga University – Dr. Soetomo General Hospital, Surabaya, Indonesia.

2 Department of Internal Medicine, Faculty of Medicine, Airlangga University – Dr. Soetomo General Hospital, Surabaya, Indonesia.


Systemic AA amyloidosis is a rare infiltrative disease representing a complication of chronic inflammatory disorders. Cardiac involvement is extremely rare and is associated with a poor prognosis. Early recognition is imperative as appropriate measures and treatment of the underlying disease may prevent death from refractory heart failure and fatal arrhythmias.
Case Report: A 53-year-old male patient with psoriatic arthritis presented with heart failure and nephrotic syndrome. Electrocardiography revealed a first-degree atrioventricular block, low-voltage QRS complexes, and a prolonged QT interval. Echocardiography revealed a hypertrophic left ventricle with normal systolic function and signs of diastolic dysfunction, as well as right ventricular dysfunction and mild pericardial effusion. An abdominal fat pad punch biopsy confirmed amyloidosis deposition. A 24-hour Holter study recorded self-terminated polymorphic ventricular arrhythmias. Immunosuppressive, anti-inflammatory, antiarrhythmic, and heart failure agents were promptly instituted, which proved ineffective.
Conclusions: Significant cardiac involvement in systemic AA amyloidosis is infrequent and complicated by fatal arrhythmias not described before. This report highlights the significance of the early recognition and aggressive control of the inflammatory response. (Iranian Heart Journal 2022; 23(2): 120-129)


  1. Pinney JH, Lachmann HJ. Systemic AA Amyloidosis. Subcell Biochem 2012; 65: 541-64. Doi: 10.1007/978-94-007-5416-4_20.
  2. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet 2018; 391: 2273-84. Doi: 10.1016/S0140-6736(18)30830-4.
  3. Browning MJ, Banks RA, Tribe CR, Hollingworth P, Kingswood C, Mackenzie JC, et al. Ten years’ experience of an amyloid clinic - a clinicopathological survey. Q J Med 1985; 54: 213-27.
  4. Gertz MA, Dispenzieri A, Sher T. Pathophysiology and treatment of cardiac amyloidosis. Nat Rev Cardiol 2015; 12: 91-102. Doi: 10.1038/nrcardio.2014.165.
  5. Nienhuis HLA, Bijzet J, Hazenberg BPC. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis 2016; 2: 10-19. Doi: 10.1159/000444206.
  6. Janssen S, Van Rijswijk MH, Meijer S, Ruinen L, Van der Hem GK. Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 1986; 29: 376-85.
  7. Lo Presti S, Mihos CG, Yucel E, Horvath SA, Santana O. Diagnosis and Management Update A Focused Review on the Pathophysiology, Diagnosis, and Management of Cardiac Amyloidosis. Rev Cardiovasc Med 2017; 18: 4170017-20. Doi: 10.3909/ricm0887.
  8. Vavricka SR, Burri E, Beglinger C, Degen L, Manz M. Serum Protein Electrophoresis: An Underused but Very Useful Test. Digestion 2009; 79: 203-10. Doi: 10.1159/000212077.
  9. Carroll JD, Gaasch WH, McAdam KPWJ. Amyloid cardiomyopathy: Characterization by a distinctive voltage/mass relation. Am J Cardiol 1982; 49: 9-13. Doi: 10.1016/0002-9149(82)90270-3.
  10. Chiu HY, Chang WL, Huang WF, Wen YW, Tsai YW, Tsai TF. Increased risk of arrhythmia in patients with psoriatic disease: A nationwide population-based matched cohort study. J Am Acad Dermatol 2015; 73: 429-38. Doi: 10.1016/j.jaad.2015.06.023.
  11. Parthenakis FI, Vardas E, Ralidis L, Dritsas A, Nihoyavnopoulos P. QT Interval in Cardiac Amyloidosis. Clin Cardiol 1996; 19: 51-4. Doi: 10.1002/clc.4960190110.
  12. Klein AL, Hatle LK, Burstow DJ, Taliercio CP, Seward JB, Kyleet RA, et al. Comprehensive Doppler assessment of right ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990; 15: 99-108. Doi: 10.1016/0735-1097(90)90183-p.
  13. Selvanayagam JB, Hawkins PN, Paul B, Myerson SG, Neubauer S. Evaluation and Management of the Cardiac Amyloidosis. J Am Coll Cardiol 2007; 50: 2101-10. Doi:10.1016/J.JACC.2007.08.028.
  14. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol 2009; 103: 411-15. Doi: 10.1016/j.amjcard.2008.09.102.
  15. Phelan D, Collier P, Thavendiranathan P, Popović ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 2012; 98: 1442-48. Doi:10.1136/heartjnl-2012-302353.
  16. Mignot A, Donal E, Zaroui A, Reant P, Salem A, Hamon C, et al. Global Longitudinal Strain as a Major Predictor of Cardiac Events in Patients with Depressed Left Ventricular Function: A Multicenter Study. J Am Soc Echocardiogr 2010; 23: 1019-24. Doi:10.1016/j.echo.2010.07.019.
  17. Baroni M, Nava S, Quattrocchi G, Milazzo A, Giannattasio C, Roghi A, et al. Role of cardiovascular magnetic resonance in suspected cardiac amyloidosis: late gadolinium enhancement pattern as mortality predictor. Netherlands Hear J 2018; 26: 34-40. Doi:10.1007/s12471-017-1046-4.
  18. Fikrle M, Paleček T, Kuchynka P, Němeček E, Bauerová L, Straub J, et al. Cardiac amyloidosis: A comprehensive review. Cor Vasa 2013; 55(1): e60-75. Doi:10.1016/J.CRVASA.2012.11.018.
  19. Van Gameren II, Hazenberg BPC, Bijzet J, Van Rijswijk MH. Diagnostic Accuracy of Subcutaneous Abdominal Fat Tissue Aspiration for Detecting Systemic Amyloidosis and Its Utility in Clinical Practice. ARTHRITIS Rheum 2006; 54: 2015-21. Doi:10.1002/art.21902.
  20. Nandakumar, Chandrasekharan R, Vijayakumar M, Thachathodiyl R. Speckle tracking as an adjunctive echocardiographic technique for differentiating cardiac amyloidosis from hypertrophic cardiomyopathy: A case study. J Indian Acad Echocardiogr Cardiovasc Imaging 2017; 1: 163. Doi: 10.4103/JIAE.JIAE_59_17.
  21. Lachmann HJ, Goodman HJB, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural History and Outcome in Systemic AA Amyloidosis. N Engl J Med 2007; 356: 2361-71. Doi:10.1056/NEJMoa070265.
  22. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-9. Doi:10.1016/S0140-6736(00)05252-1.
  23. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63: 1285-8. Doi: 10.1161/01.cir.63.6.1285.